AbbVie, Teva must face US antitrust case over Niaspan, judge concludes
( October 30, 2026, 22:31 GMT | Official Statement) -- MLex Summary: AbbVie and Teva Pharmaceuticals failed to win summary judgment in a US case accusing them of conspiring to delay generic Niaspan. “We conclude that the undisputed evidence shows that the settlement caused plaintiffs the injury necessary to establish antitrust standing. There is a genuine dispute as to whether the reverse payment settlement violated antitrust laws because it was a payment to delay the entry of the generic into the market to eliminate competition. There are also material issues of fact as to the relevant antitrust market,” District Judge Timothy J. Savage concluded. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.